The Cardiac Uraemic fibrosis Detection in DiaLysis patiEnts study

Not Applicable

Completed

• Conditions: Renal failure; Urological and Genital Diseases

• Registration Number: ISRCTN99591655
• Lead Sponsor: HS Greater Glasgow and Clyde (UK)

Brief Summary

2017 results in: https://www.ncbi.nlm.nih.gov/pubmed/29070834

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-07-16
• Study Completion: 2017-06-01
• Last Update Posted: 10 September 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Adult patients who have been treated with haemodialysis for <1 year are eligible

Exclusion Criteria

1. Live donor transplant planned during the next 6 months
2. Predicted life expectancy <6months
3. Inability to give informed consent
4. Contraindications to MRI imaging (pacemaker, extreme claustrophobia)
5. Atrial fibrillation (makes gating of CMR images difficult)

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Volume of myocardial fibrosis on cardiac MRI scanning. This will be measured by MRI scanning of the heart at baseline and on a follow up MRI 6 months later.

Secondary Outcome Measures

Name	Time	Method
1. Change in serum brain natriuretic peptide<br>2. Simple correlations will be tested between presence/volume of fibrosis and serum markers of cardiac muscle enlargements/fibrosis and features of arrhythmia on ECG (heart tracing)<br><br>Measured at baseline and 6 months later